Pioneering Preclinical Research in
Osteoarthritis Treatment
Unlocking the Science Behind Verapamil: Breakthroughs in Pain Relief and Calcium Signaling.
With over 40 years of orthopedic experience and 20 years of dedicated research, Dr. David Waddell, Calosyn’s founder, has been at the forefront of osteoarthritis treatment. His extensive studies on verapamil as a therapeutic for osteoarthritis have led to groundbreaking results, including three IRB studies that demonstrate significant pain reduction in patients.
Discovered the finding that synovial tissue from explanted human osteoarthritic synovium is aberrant in its calcium channel density and calcium channel-mediated signaling.
Demonstrated a direct connection between aberrant calcium signaling and the release of matrix metalloproteinases from human osteoarthritic synovium, and showed the ability of calcium channel blockers to decrease the release of metalloproteinases.